Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 47
- Registration Number
- NCT01780220
- Locations
- 🇫🇷
Centre François Baclesse, Caen, France
🇫🇷Institut de Cancérologie de l'ouest/René Gauducheau, Saint-Herblain, France
🇫🇷Centre Leon Berard, Lyon, France
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT01756638
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 124
- Registration Number
- NCT01751451
- Locations
- 🇺🇸
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
🇺🇸Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸NorthShore University Health System, Long Island City, New York, United States
BKM120+Abiraterone Acetate for Metastatic CRPC
- Conditions
- Interventions
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 4
- Registration Number
- NCT01741753
- Locations
- 🇺🇸
Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Abiraterone Acetate Trial in African American Prostate Cancer Patients
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 11
- Registration Number
- NCT01735396
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Queens Cancer Center, Queens Hospital, New York, New York, United States
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Charles Ryan
- Target Recruit Count
- 6
- Registration Number
- NCT01717898
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Duke University
- Target Recruit Count
- 37
- Registration Number
- NCT01717053
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Durham Regional Hospital, Durham, North Carolina, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1209
- Registration Number
- NCT01715285
A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 214
- Registration Number
- NCT01695135
Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Janssen Pharmaceutica
- Registration Number
- NCT01692483
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.